Affiliation:
1. Division of Immunology, LCMN, Germans Trias i Pujol University Hospital and Research Institute , Campus Can Ruti, Badalona , Spain
2. Department of Cellular Biology, Physiology and Immunology, Universitat Autònoma de Barcelona , 08193 Bellaterra (Cerdanyola del Vallès) , Spain
3. Translational and Clinical Research Institute, Newcastle University , Newcastle upon Tyne , UK
Abstract
Summary
Tolerogenic dendritic cells (tolDCs) are a promising strategy to treat autoimmune diseases since they have the potential to re-educate and modulate pathological immune responses in an antigen-specific manner and, therefore, have minimal adverse effects on the immune system compared to conventional immunosuppressive treatments. TolDC therapy has demonstrated safety and efficacy in different experimental models of autoimmune disease, such as multiple sclerosis (MS), type 1 diabetes (T1D), and rheumatoid arthritis (RA). Moreover, data from phase I clinical trials have shown that therapy with tolDCs is safe and well tolerated by MS, T1D, and RA patients. Nevertheless, various parameters need to be optimized to increase tolDC efficacy. In this regard, one important parameter to be determined is the most appropriate route of administration. Several delivery routes, such as intravenous, subcutaneous, intraperitoneal, intradermal, intranodal, and intraarticular routes, have been used in experimental models as well as in phase I clinical trials. This review summarizes data obtained from preclinical and clinical studies of tolDC therapy in the treatment of MS, T1D, and RA and their animal models, as well as data from the context of cancer immunotherapy using mature peptide-loaded DC, and data from in vivo cell tracking experiments, to define the most appropriate route of tolDC administration in relation to the most feasible, safest, and effective therapeutic use.
Funder
European Union’s Horizon 2020
ISCIII-Subdirección General de Evaluación
Fondo Europeo de Desarrollo Regional
Government of Catalonia
Publisher
Oxford University Press (OUP)
Reference63 articles.
1. LPS-treated bone marrow-derived dendritic cells induce immune tolerance through modulating differentiation of CD4+ regulatory T cell subpopulations mediated by 3G11 and CD127;Zhou,2017
2. Apoptotic cell-treated dendritic cells induce immune tolerance by specifically inhibiting development of CD4+ effector memory T cells;Zhou,2016
3. Combined therapy of vitamin D3-Tolerogenic dendritic cells and interferon-β in a preclinical model of multiple sclerosis;Quirant-Sánchez,2021
4. 1,25-dihydroxyvitamin D3-induced dendritic cells suppress experimental autoimmune encephalomyelitis by increasing proportions of the regulatory lymphocytes and reducing T helper type 1 and type 17 cells;Xie,2017
5. Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis;Li,2017
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献